Xencor Company Profile (NASDAQ:XNCR)

About Xencor

Xencor logoXencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. Its clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. Its oncology product candidates are in preclinical stage, which include XmAb14045 and XmAb13676. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 and XmAb13551.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XNCR
  • CUSIP:
Key Metrics:
  • Previous Close: $20.56
  • 50 Day Moving Average: $22.91
  • 200 Day Moving Average: $18.16
  • 52-Week Range: $9.89 - $26.50
  • Trailing P/E Ratio: 21.85
  • Foreward P/E Ratio: -19.40
  • P/E Growth: 0.00
  • Market Cap: $841.91M
  • Outstanding Shares: 40,949,000
  • Beta: 2.11
  • Net Margins: 39.07%
  • Return on Equity: 22.53%
  • Return on Assets: 16.26%
  • Current Ratio: 2.10%
  • Quick Ratio: 2.10%
Additional Links:
Companies Related to Xencor:

Analyst Ratings

Consensus Ratings for Xencor (NASDAQ:XNCR) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.83 (25.65% upside)

Analysts' Ratings History for Xencor (NASDAQ:XNCR)
DateFirmActionRatingPrice TargetDetails
10/4/2016Piper Jaffray Cos.Initiated CoverageOverweight$35.00View Rating Details
9/12/2016Canaccord GenuitySet Price TargetBuy$27.00View Rating Details
9/12/2016WedbushReiterated RatingOutperform$27.00View Rating Details
6/29/2016Leerink SwannReiterated RatingOutperform$18.00View Rating Details
5/2/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00View Rating Details
8/5/2015MLV & Co.Reiterated RatingBuy$22.00 -> $29.00View Rating Details
5/6/2015Credit Suisse Group AGInitiated CoverageOutperform$14.00View Rating Details
(Data available from 10/27/2014 forward)


Earnings History for Xencor (NASDAQ:XNCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2016Q216($0.18)$1.13$7.43 million$66.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.27)($0.16)$3.50 million$7.30 millionViewN/AView Earnings Details
3/7/2016Q415($0.30)$0.19$2.50 million$21.80 millionViewN/AView Earnings Details
11/3/2015Q315($0.17)($0.25)$3.57 million$3.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.18)($0.22)$1.90 million$1.01 millionViewN/AView Earnings Details
5/4/2015Q115($0.17)($0.19)$1.80 millionViewListenView Earnings Details
2/19/2015($0.22)($0.04)ViewN/AView Earnings Details
11/10/2014Q3 14($0.19)($0.20)ViewN/AView Earnings Details
7/31/2014($0.19)($0.16)ViewN/AView Earnings Details
5/14/2014Q1 14($0.16)($0.12)$1.71 million$2.20 millionViewN/AView Earnings Details
3/19/2014Q413($0.14)($0.24)$1.71 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Xencor (NASDAQ:XNCR)
Current Year EPS Consensus Estimate: $0.56 EPS
Next Year EPS Consensus Estimate: $-1.06 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.35)($0.21)($0.26)
Q2 20164($0.36)($0.23)($0.28)
Q3 20163($0.37)$0.06($0.20)
Q4 20163($0.29)$0.06($0.06)
Q1 20171$0.03$0.03$0.03
Q2 20171$0.00$0.00$0.00
Q3 20171($0.02)($0.02)($0.02)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)


Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Xencor (NASDAQ:XNCR)
Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 67.42%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Edgardo Baracchini JrInsiderSell10,000$25.35$253,500.00View SEC Filing  
9/27/2016John S Stafford IIIMajor ShareholderSell40,000$25.72$1,028,800.00View SEC Filing  
9/2/2016Edgardo Baracchini JrInsiderSell10,000$21.06$210,600.00View SEC Filing  
8/30/2016Bassil I DahiyatInsiderSell40,000$21.80$872,000.00View SEC Filing  
8/26/2016John S Stafford IIIMajor ShareholderSell24,351$21.48$523,059.48View SEC Filing  
8/24/2016John J KuchVPSell25,000$21.95$548,750.00View SEC Filing  
8/23/2016John R DesjarlaisVPSell16,294$21.73$354,068.62View SEC Filing  
8/23/2016John S Stafford IIIMajor ShareholderSell96,828$21.73$2,104,072.44View SEC Filing  
8/16/2016Bassil I DahiyatInsiderSell45,886$22.06$1,012,245.16View SEC Filing  
8/15/2016Bruce L A CarterDirectorSell3,400$22.67$77,078.00View SEC Filing  
8/15/2016John S Stafford IIIMajor ShareholderSell10,000$23.06$230,600.00View SEC Filing  
8/11/2016John S Stafford IIIMajor ShareholderSell30,500$21.87$667,035.00View SEC Filing  
8/10/2016Edgardo Baracchini JrInsiderSell2,500$21.83$54,575.00View SEC Filing  
8/3/2016Edgardo Baracchini, Jr.InsiderSell4,528$20.00$90,560.00View SEC Filing  
8/3/2016John R. DesjarlaisVPSell5,905$20.00$118,100.00View SEC Filing  
7/11/2016Edgardo Baracchini JrInsiderSell1,250$18.13$22,662.50View SEC Filing  
6/28/2016Edgardo Baracchini JrInsiderSell1,250$15.10$18,875.00View SEC Filing  
5/24/2016Bassil I DahiyatCEOSell45,886$13.00$596,518.00View SEC Filing  
4/7/2016Edgardo Baracchini JrInsiderSell3,750$15.00$56,250.00View SEC Filing  
3/17/2016Bassil I DahiyatCEOSell45,886$11.02$505,663.72View SEC Filing  
3/3/2016John R DesjarlaisVPSell14,260$12.01$171,262.60View SEC Filing  
2/1/2016John S Stafford IIIMajor ShareholderSell25$10.79$269.75View SEC Filing  
1/29/2016John S Stafford IIIMajor ShareholderBuy25$10.83$270.75View SEC Filing  
1/4/2016John R. DesjarlaisVPSell1,100$14.13$15,543.00View SEC Filing  
12/17/2015John J KuchVPSell4,781$14.89$71,189.09View SEC Filing  
12/16/2015Paul A. FosterinsiderSell6,025$15.01$90,435.25View SEC Filing  
12/3/2015John S. Stafford IIIDirectorSell30,000$15.13$453,900.00View SEC Filing  
11/25/2015Edgardo Baracchini, Jr.insiderSell2,500$15.00$37,500.00View SEC Filing  
9/3/2015John S Stafford IIIDirectorSell10,000$17.22$172,200.00View SEC Filing  
9/1/2015Edgardo Baracchini, Jr.insiderSell1,250$16.49$20,612.50View SEC Filing  
7/6/2015John S Stafford IIIDirectorSell10,000$22.29$222,900.00View SEC Filing  
7/1/2015Edgardo Baracchini JrInsiderSell2,500$22.24$55,600.00View SEC Filing  
6/16/2015John S Stafford IIIDirectorSell20,000$20.35$407,000.00View SEC Filing  
6/15/2015Bruce L A CarterDirectorSell10,000$19.21$192,100.00View SEC Filing  
6/15/2015Edgardo Baracchini JrInsiderSell1,277$19.85$25,348.45View SEC Filing  
6/12/2015John J KuchVPSell8,756$19.35$169,428.60View SEC Filing  
6/12/2015John S Stafford IIIDirectorSell250,000$19.00$4,750,000.00View SEC Filing  
6/3/2015John S Stafford IIIDirectorSell10,000$18.76$187,600.00View SEC Filing  
6/1/2015Edgardo Baracchini JrInsiderSell1,250$18.14$22,675.00View SEC Filing  
5/26/2015John S Stafford IIIDirectorSell10,000$17.01$170,100.00View SEC Filing  
5/15/2015Edgardo Baracchini JrInsiderSell1,604$15.00$24,060.00View SEC Filing  
8/11/2014John S Stafford IIIDirectorSell124,000$9.37$1,161,880.00View SEC Filing  
12/6/2013John S Stafford IIIDirectorBuy275,000$5.50$1,512,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Xencor (NASDAQ:XNCR)
publicnow.com logoXencor to Host Third Quarter 2016 Financial Results Webcast and Conference Call on November 2, 2016 (NASDAQ:XNCR)
www.publicnow.com - October 26 at 12:02 PM
investornewswire.com logoXencor, Inc. (NASDAQ:XNCR) Buy Calls At 0 - Investor Newswire (NASDAQ:XNCR)
www.investornewswire.com - October 25 at 8:20 PM
News IconSEC 13F Narrative: Perceptive Advisors LLC Decreased Its Holding in Xencor INC (XNCR) by $4.95 Million as Market ... - Chester News (NASDAQ:XNCR)
www.chesterindependent.com - October 21 at 8:12 PM
News IconMaking Headway as Stock Popping Mid-session: Xencor, Inc. (NASDAQ:XNCR) - CSZ News (NASDAQ:XNCR)
cincysportszone.com - October 20 at 8:29 PM
investornewswire.com logoAnalysts Set EPS Target At $-0.25 For Xencor, Inc. (NASDAQ:XNCR) - Investor Newswire (NASDAQ:XNCR)
www.investornewswire.com - October 19 at 7:49 PM
investornewswire.com logoSell Recommendations For Xencor, Inc. (NASDAQ:XNCR) At 0 - Investor Newswire (NASDAQ:XNCR)
www.investornewswire.com - October 18 at 7:59 PM
News IconInsiders are Scaling Back Holdings in Xencor, Inc. (NASDAQ:XNCR) - CSZ News (NASDAQ:XNCR)
cincysportszone.com - October 18 at 5:46 AM
capitalcube.com logoXencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : October 13, 2016 (NASDAQ:XNCR)
www.capitalcube.com - October 13 at 12:17 PM
finance.yahoo.com logoCoverage initiated on Xencor by Piper Jaffray (NASDAQ:XNCR)
finance.yahoo.com - October 4 at 7:40 PM
finance.yahoo.com logoPreliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease to be presented at American College of Rheumatology (ACR) 2016 Annual Meeting (NASDAQ:XNCR)
finance.yahoo.com - October 3 at 7:35 PM
biz.yahoo.com logoXENCOR INC Files SEC form 8-K, Other Events (NASDAQ:XNCR)
biz.yahoo.com - September 30 at 7:24 PM
capitalcube.com logoETF’s with exposure to Xencor, Inc. : September 21, 2016 (NASDAQ:XNCR)
www.capitalcube.com - September 21 at 12:01 PM
biz.yahoo.com logoXENCOR INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:XNCR)
biz.yahoo.com - September 20 at 8:02 AM
publicnow.com logoXencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195 (NASDAQ:XNCR)
www.publicnow.com - September 15 at 11:59 AM
finance.yahoo.com logoXencor (XNCR) Doses First Patient in Myeloid Leukemia Trial (NASDAQ:XNCR)
finance.yahoo.com - September 14 at 12:36 PM
publicnow.com logoXencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute Myeloid Leukemia and Other CD123-Expressing Hematologic Malignancies (NASDAQ:XNCR)
www.publicnow.com - September 12 at 7:38 PM
fool.com logoThis Caused Xencor Inc.'s Stock to Jump 11.6% in August (NASDAQ:XNCR)
www.fool.com - September 10 at 8:54 AM
fxpips.com logoTop 20 NASDAQ Most Declined Stocks, Sept. 6 (NASDAQ:XNCR)
www.fxpips.com - September 6 at 5:42 AM
capitalcube.com logoETF’s with exposure to Xencor, Inc. : September 1, 2016 (NASDAQ:XNCR)
www.capitalcube.com - September 1 at 11:34 AM
capitalcube.com logoXencor, Inc. :XNCR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:XNCR)
www.capitalcube.com - August 15 at 8:42 PM
investing.com logo4 Stocks To Watch: ADXS, XNCR, LB, RRGB (NASDAQ:XNCR)
www.investing.com - August 4 at 11:40 AM
twst.com logoXencor Inc.: Xencor Reports Second Quarter 2016 Financial Results (NASDAQ:XNCR)
www.twst.com - August 4 at 11:40 AM
sg.finance.yahoo.com logoXencor posts 2Q profit (NASDAQ:XNCR)
sg.finance.yahoo.com - August 2 at 8:47 PM
investing.com logo4 Stocks To Watch: EXAS, NKTR, OLED, XNCR (NASDAQ:XNCR)
www.investing.com - August 2 at 5:55 AM
ftsenews.co.uk logoXencor, Inc. (XNCR) Updated Price Targets - FTSE News (NASDAQ:XNCR)
www.ftsenews.co.uk - July 28 at 8:52 PM
finance.yahoo.com logoShould You Buy Xencor (XNCR) Ahead of Earnings? (NASDAQ:XNCR)
finance.yahoo.com - July 28 at 10:03 AM
investornewswire.com logoCan Shares Of Xencor, Inc. (NASDAQ:XNCR) Hit $27? - Investor Newswire (NASDAQ:XNCR)
www.investornewswire.com - July 26 at 8:56 PM
publicnow.com logoXencor to Host Second Quarter 2016 Financial Results Webcast and Conference Call on August 2, 2016 (NASDAQ:XNCR)
www.publicnow.com - July 26 at 8:18 AM
fiscalstandard.com logoXencor, Inc. (XNCR) Current Analyst Ratings - Fiscal Standard (NASDAQ:XNCR)
www.fiscalstandard.com - July 23 at 10:01 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Xencor, Inc. (NASDAQ:XNCR) - TGP (NASDAQ:XNCR)
telanaganapress.com - July 21 at 8:44 PM
News IconAre Analysts Bearish Xencor Inc (NASDAQ:XNCR) After Last Week? - Consumer Eagle (NASDAQ:XNCR)
www.consumereagle.com - July 21 at 8:44 PM
News IconXencor, Inc. (NASDAQ:XNCR): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:XNCR)
www.engelwooddaily.com - July 19 at 8:34 PM
investornewswire.com logoIs $27 Price Target Attainable For Xencor, Inc. (NASDAQ:XNCR)? - Investor Newswire (NASDAQ:XNCR)
www.investornewswire.com - July 19 at 8:34 PM
News IconStock in Positive Territory for the Quarter: Xencor, Inc. (NASDAQ:XNCR) - Engelwood Daily (NASDAQ:XNCR)
www.engelwooddaily.com - July 18 at 5:50 AM
News IconTrading Performance and Target Watch for Xencor, Inc. (NASDAQ:XNCR) - Press Telegraph (NASDAQ:XNCR)
presstelegraph.com - July 18 at 5:50 AM
News IconShare Performance Summary for: Xencor, Inc. (NASDAQ:XNCR) - Press Telegraph (NASDAQ:XNCR)
presstelegraph.com - July 18 at 5:50 AM
News IconShares Experiencing a Downtrend: Xencor, Inc. (NASDAQ:XNCR) - TGP (NASDAQ:XNCR)
telanaganapress.com - July 16 at 11:32 AM
fiscalstandard.com logoBroker Outlook For Xencor, Inc. (XNCR) - Fiscal Standard (NASDAQ:XNCR)
www.fiscalstandard.com - July 16 at 11:32 AM
nasdaq.com logoWhy Xencor (XNCR) is Poised to Beat Earnings Estimates Again (NASDAQ:XNCR)
www.nasdaq.com - July 13 at 11:12 AM
News IconXencor, Inc. (NASDAQ:XNCR) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:XNCR)
www.engelwooddaily.com - July 12 at 8:36 PM
investornewswire.com logoStrong Sell Calls For Xencor, Inc. (NASDAQ:XNCR) At 0 - Investor Newswire (NASDAQ:XNCR)
www.investornewswire.com - July 12 at 8:36 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: AK Steel, Gulfport Energy, Hecla Mining, Carrizo Oil & Gas and Xencor (NASDAQ:XNCR)
finance.yahoo.com - July 12 at 9:30 AM
News IconStock on the Rise for the Quarter: Xencor, Inc. (NASDAQ:XNCR) - Engelwood Daily (NASDAQ:XNCR)
www.engelwooddaily.com - July 11 at 8:12 PM
News IconStock Performance Rundown on: Xencor, Inc. (NASDAQ:XNCR) - Press Telegraph (NASDAQ:XNCR)
presstelegraph.com - July 11 at 8:12 PM
News Icon1.24 is Xencor Inc's (NASDAQ:XNCR) Institutional Investor Sentiment - Press Telegraph (NASDAQ:XNCR)
presstelegraph.com - July 11 at 8:12 PM
finance.yahoo.com logoCan The Uptrend Continue for Xencor (XNCR)? (NASDAQ:XNCR)
finance.yahoo.com - July 6 at 4:17 AM
finance.yahoo.com logoCan Xencor (XNCR) Run Higher on Strong Earnings Estimate Revisions? (NASDAQ:XNCR)
finance.yahoo.com - July 5 at 8:45 AM
prnewswire.com logoXencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676 (NASDAQ:XNCR)
www.prnewswire.com - June 29 at 11:02 AM
nasdaq.com logoXencor Inc. (XNCR) Is Climbing After Novartis Collaboration Agreement (NASDAQ:XNCR)
www.nasdaq.com - June 29 at 11:02 AM
rttnews.com logoXencor Inc. (XNCR) Surged To A 6-Month High On Novartis Collaboration (NASDAQ:XNCR)
www.rttnews.com - June 29 at 11:02 AM


Xencor (NASDAQ:XNCR) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by MarketBeat.com Staff